(Q33437790)

26 July 2017

Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma (English)

1 reference

26 July 2017

1 reference

Kenshi Suzuki

1

1 reference

26 July 2017

Hiroshi Handa

2

1 reference

26 July 2017

Takaaki Chou

3

1 reference

26 July 2017

Kenichi Ishizawa

4

1 reference

26 July 2017

Takatoshi Takubo

5

1 reference

26 July 2017

Yoichi Kase

6

1 reference

26 July 2017

20 December 2016

1 reference

International Journal of Hematology

26 July 2017

1 reference

26 July 2017

105

1 reference

26 July 2017

445-452

1 reference

26 July 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-016-2149-1

26 July 2017

0 references

cites work

Epidemiology of multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Epidemiology and Burden of Multiple Myeloma in Japan: a Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Racial/ethnic differences in drug disposition and response: review of recently approved drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2149-1

Predictability of the effects of race or ethnicity on pharmacokinetics of drugs.

21 January 2018

1 reference

12 December 2020

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

1 reference

12 December 2020

Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference

1 reference

12 December 2020

The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies

1 reference

12 December 2020

10.1007/S12185-016-2149-1

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference